Teva makes two senior executive appointments
pharmafile | August 3, 2012 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing | Aharon (Arik) Yaari, Carlo De Notaristefani, Teva
Teva has announced the appointments of Dr Carlo De Notaristefani as president and chief executive of Global Operations, and Aharon (Arik) Yaari as the executive VP to its newly-created Community and Institutional Affairs unit.
Both De Notaristefani (pictured) and Yaari will report directly to Dr Jeremy Levin, president and chief executive of Teva and will join the executive team.
“We are delighted to have Carlo and Arik in these roles,” said Levin. “Teva has a bright future, and I am confident Carlo and Arik will provide critical insight and expertise as the global healthcare market continues to evolve.”
De Notaristefani will have responsibility for Teva’s product supply and its manufacturing network. He will collaborate closely with Frances Zipp, executive VP of Quality, who is also a member of the executive team, reporting to Levin.
De Notaristefani has over 25 years of international experience with extensive technical, operational, manufacturing and P&L experience. Recently, De Notaristefani was at Bristol-Myers Squibb where he served as president, Technical Operations and Global Support Functions.
“I am extremely proud to join Teva, and to have the opportunity to contribute to the Company’s long tradition of excellence, which was established through its Israeli heritage and today continues as it creates a global organisation with a unique combination of innovation, focus and discipline in execution,” he said.
As part of its strategic objectives, Teva has established an organisation of Community and Institutional Affairs. This will be led by Yaari who will build a strategy to enhance public well-being by drawing on Teva’s competencies in developing and manufacturing products to address the unmet needs of patients.
“In assuming my new role, I am excited about the opportunity to enhance Teva’s involvement in communities around the globe and to expand Teva’s commitment to social responsibility and philanthropy, which is an integral part of the Company’s heritage,” said Yaari.
Yaari joined Teva in 1981, and has served in significant key positions at Teva, such as group VP, Global API, and most recently as group VP, Teva Generics Systems.
Related Content
Teva’s Ajovy significantly reduces migraine in children and adolescents
Teva’s Ajovy (fremanezumab) has demonstrated significant reduction in monthly migraine and headache days in children …
Teva announces positive results from trial of AJOVY for migraine
Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its …
Sanofi and Teva partner for development of inflammatory bowel disease treatment
Sanofi and Teva Pharmaceuticals have announced that they will collaborate for the co-development and co-commercialisation …
